FCCC LOGO Faculty Publications
Serna A , Ramirez MC , Soukhanova A , Sigal LJ
Cutting edge: Efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells
Journal of Immunology. 2003 Dec;171(11) :5668-5672
Back to previous list
Abstract
Priming of CD8(+) T cells requires presentation of short peptides bound to MHC class I molecules of professional AM. Cross-presentation is a mechanism where by professional APC present on their own MHC class I molecules peptides derived from degradation of Ags synthesized by other Ag "donor cells." The mechanism of cross-presentation is poorly understood, and the nature of the transferred Ag is unknown. In this report, we demonstrate that the bulk of a cross-presented Ag transferred from donor cells recently infected with vaccinia virus are proteasomal products that are susceptible to peptidases within the donor cell cytosol and not full-length proteins or mature epitopes either free or bound to chaperones.
Notes
English Article KeyWords Plus: EXOGENOUS ANTIGEN; THIMET OLIGOPEPTIDASE; IMMUNE-RESPONSES; PEPTIDES; DEGRADATION; GENERATION; PROTEIN; MOLECULES; PATHWAY; VIVO Sigal, LJ; *Fox* *Chase* Canc Ctr, Div Basic Sci, Virol Working Grp, 333 Cottman Ave, Philadelphia, PA 19111 USA. Research Addresses: *Fox* *Chase* Canc Ctr, Div Basic Sci, Virol Working Grp, Philadelphia, PA 19111 USA. Cited References: ANDERSON K, 1991, J EXP MED, V174, P489 BENINGA J, 1998, J BIOL CHEM, V273, P18734 DEBRICK JE, 1991, J IMMUNOL, V147, P2846 ELROYSTEIN O, 1992, CURRENT PROTOCOLS MO, V2 ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743 FENTEANY G, 1995, SCIENCE, V268, P726 GOLDBERG AL, 2002, MOL IMMUNOL, V39, P147 KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020 KISSELEV AF, 1999, J BIOL CHEM, V274, P3363 KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243 LENZ LL, 2000, J EXP MED, V192, P1135 MENG LH, 1999, P NATL ACAD SCI USA, V96, P10403 MOORE MW, 1988, CELL, V54, P777 NORBURY CC, 2003, CURR OPIN IMMUNOL, V15, P82 PFEIFER JD, 1993, NATURE, V361, P359 PRINCIOTTA MF, 2003, IMMUNITY, V18, P343 REITS E, 2003, IMMUNITY, V18, P97 REMIREZ MC, 2002, J IMMUNOL, V169, P6733 ROCK KL, 1999, ANNU REV IMMUNOL, V17, P739 ROCK KL, 2002, ADV IMMUNOL, V80, P1 ROCK KL, 1990, SCIENCE, V249, P918 SARIC T, 2001, J BIOL CHEM, V276, P36474 SCHUBERT U, 2000, NATURE, V404, P770 SIGAL LJ, 1999, NATURE, V398, P77 SIGAL LJ, 2000, J EXP MED, V192, P1143 SRIVASTAVA P, 2002, ANNU REV IMMUNOL, V20, P395 YEWDELL JW, 1999, ADV IMMUNOL, V73, P1 YORK IA, 2003, IMMUNITY, V18, P429 Number of cited references: 28 Number of times cited: 0 Publisher: AMER ASSOC IMMUNOLOGISTS; 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA. 0022-1767